Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for RenovoRx, Inc. (RNXT : NSDQ)

• Company Description    RenovoRx Inc. is a biopharmaceutical company. It developed a therapy platform targeting difficult-to-treat tumors. RenovoRx Inc. is headquartered in Silicon Valley, California. Number of Employees: 10

• Price / Volume Information    Yesterday's Closing Price: $1.34 Daily Weekly Monthly 20 Day Moving Average: 129,153 shares Shares Outstanding: 36.57 (millions) Market Capitalization: $49.01 (millions) Beta: 1.27 52 Week High: $1.69 52 Week Low: $0.75 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -1.47% -5.16% 12 Week 31.37% 10.50% Year To Date 3.88% -2.72%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2570 West El Camino Real Suite 320 - Mountain View,CA 94040 USA ph: 650-284-4433 fax: 650-397-4433 renovorx@kcsa.com http://www.renovorx.com

• General Corporate Information    Officers Shaun R. Bagai - Chief Executive Officer; Director Ramtin Agah - Chairman of the Board of Directors Ronald B. Kocak - Vice President; Controller and Principal Accountin Laurence J. Marton - Director Una S. Ryan - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 75989R107 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/12/25 Share - Related Items Shares Outstanding: 36.57 Most Recent Split Date: (:1) Beta: 1.27 Market Capitalization: $49.01 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.08 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.31 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.72 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -14.29% vs. Previous Quarter: 33.33% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: 358.14% ROE 06/30/25 - - 03/31/25 - -119.58 12/31/24 - -156.08 ROA 06/30/25 - - 03/31/25 - -88.01 12/31/24 - -100.90 Current Ratio 06/30/25 - - 03/31/25 - 9.07 12/31/24 - 4.10 Quick Ratio 06/30/25 - - 03/31/25 - 9.07 12/31/24 - 4.10 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - -4,232.50 12/31/24 - -20,497.67 Book Value 06/30/25 - - 03/31/25 - 0.36 12/31/24 - 0.19 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©